Panbela Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Panbela TherapeuticsSe prevé que los beneficios de la empresa disminuyan en 4.3% al año, mientras que sus ingresos anuales crecerán en 82.4% al año. Se espera que el BPA de grow sea de 53% al año.

Información clave

-4.3%

Tasa de crecimiento de los beneficios

53.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.7%
Tasa de crecimiento de los ingresos	82.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Apr 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:X70 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-52	N/A	N/A	2
12/31/2024	N/A	-32	N/A	N/A	2
12/31/2023	N/A	-22	N/A	N/A	2
12/31/2022	N/A	-35	-16	-15	N/A
9/30/2022	N/A	-34	-13	-12	N/A
6/30/2022	N/A	-31	-12	-12	N/A
3/31/2022	N/A	-12	-9	-9	N/A
12/31/2021	N/A	-10	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-4	-4	N/A
9/30/2020	N/A	-5	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-6	-3	-3	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-6	-2	-2	N/A
6/30/2019	N/A	-6	-2	-2	N/A
3/31/2019	N/A	-6	-3	-3	N/A
12/31/2018	N/A	-6	-2	-2	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-7	-3	-3	N/A
12/31/2017	N/A	-10	-3	-3	N/A
9/30/2017	N/A	-10	-3	-3	N/A
6/30/2017	N/A	-10	-4	-4	N/A
3/31/2017	N/A	-10	-3	-3	N/A
12/31/2016	N/A	-5	-2	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: X70 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: X70 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: X70 se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: X70 no tendrá ingresos el año que viene.

Ingresos de alto crecimiento: X70 no tendrá ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de X70 se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Panbela Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento